View Abstract

A7346 - Characterization of the Population with Non-Small Cell Lung Cancer in a Reference Healthcare Center in Latin-America
Author Block: L. Fernandez1, V. Zuñiga2, J. F. Henao3, L. F. Sua Villegas4, Biomedical Research Group in Thorax; 1Interventional Pulmonology, Fundacion Valle del Lili, Universidad Icesi, Cali, Colombia, 2Medical Student, Fundacion Valle del Lili, Universidad Icesi, Cali, Colombia, 3Internal Medicine, Fundacion Valle del Lili, Universidad Icesi, Cali, Colombia, 4Department of Pathology and Laboratory Medicine, Fundacion Valle del Lili, Universidad Icesi, Calli, Colombia.
RATIONALE Non-small cell lung cancer (NSCLC) is the most prevalent histological variety of lung cancer worldwide and, within this classification, adenocarcinoma is the most common. Therapeutic targets such as mutations in the EGFR and ALK genes have been identified, with significantly lower mortality rates, data regarding the mutational status and clinical outcomes with targeted therapy with tirosin kinase inhibitors (TKI) in a population is necessary, not only for epidemiological purposes, but for improving quality of health care given to these patients. METHODS Our series included 114 patients diagnosed with NSCLC between 2013 and 2016 at a reference health care center in Colombia, excluding those referred for the sole purpose of genetic testing. Each medical record was revised at the time of diagnosis and three and six month follow-up. We recorded demographic, clinical, histological data, and mutations of EGFR and ALK genes. During the follow-up consultations we registered information about the type of treatment, presence of metastases, change in the TNM staging, presence of toxicity due to TKI and death. We also reported the experience regarding the follow-up at three and six months, and the survival probability within the same period. RESULTS The mean age was 65 ± 12 years. 72.8% (n=83) of patients were classified as stage IV. Adenocarcinoma was the most frequent (80.7%; n=92). The prevalence for EGFR mutations was 27% (n=30) and for ALK was 15.8% (n=9). survival probability at 90 days was 83.6% and 63.3% at 180 days. Due to procedural circumstances within Colombian healthcare system, in our population, follow-up was not performed as recommended by international guidelines. Probability of survival at six months was based on information from 40% of the initial sample. There was a trend towards reduced availability of information in later months. CONCLUSION The prevalence of EGFR mutations was similar to that reported worldwide, and fusions in the EML4-ALK gene were higher than expected. We found an association between being a non-smoker and the presence of mutations, as reported in the worldwide literature. Healthcare services and molecular diagnostic technologies should be provided in a comprehensive manner and the responsibility for providing them cannot be fragmented at the expense of the patient's health.